Biotec Services International completes its rebrand into PCI Group
BRIDGEND, Wales, Feb. 9, 2015 /PRNewswire/ -- PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has today rebranded as part of the PCI group.
Photo - http://photos.prnewswire.com/prnh/20150206/174101
This rebrand brings together the expertise of two world class organizations and significantly expands PCI's capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products.
The broad range of services includes manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for optimal clinical package design, global logistics planning and depot management over a wide range of temperatures from controlled ambient to -196 degrees C, a service for which Biotec is known across the globe.
Dr Fiona Withey, Managing Director, UK Clinical Services, stated, "The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization."
Biotec recently announced the completion of an expansion to its Bridgend facilities. This development significantly expands the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain expertise solutions — supporting medicines from +25 degrees C down to -196 degrees C. The enhanced Bridgend facilities are an important part of PCI's network of sites encompassing both Europe and North America, providing clinical and commercial medicines to over 100 countries globally.
About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives. For more information please visit www.pciservices.com or follow us on Twitter at @PCI_Social.
Contact
Becky Griffiths
Marketing Manager
becky.griffiths@pciservices.com
+44 7919 560749
Share this article